Siemens Atellica CH A1c test recalled for possible bias in results
Siemens Healthcare Diagnostics is recalling all lots of the Atellica CH Enzymatic Hemoglobin A1c (A1c_E) assay. The notice says there is a potential for intermittent well-to-well bias on Atellica CH and Atellica CI analyzers, which could cause falsely depressed or falsely elevated HbA1c patient results. No injuries have been reported.
From the FDA notice · Read the official notice ↗ · All Siemens recalls
What to do
- Stop using the affected A1c_E assay, material number 11097536, on all lots.
- Identify affected product by material number 11097536 and UDI-DI 00630414220505. All lot numbers are included.
- Contact Siemens Healthcare Diagnostics for next steps. The notice doesn't specify a remedy, such as a replacement or correction.
Is yours affected?
Compare your label or packaging with the recalled product.
- Product
- Atellica CH Enzymatic Hemoglobin A1c (A1c_E). Material Number: 11097536.
- Sold in
- Nationwide
- Made for
- All ages (0 months and older)
Details
- Units affected
- 24,077 units
- Illnesses reported
- None reported
- Manufactured in
- 511 Benedict Ave, N/A, Tarrytown, NY, United States
- Classification
- Class II
- Recall number
- Z-2703-2026
In the FDA's words
- Description
- Atellica CH Enzymatic Hemoglobin A1c (A1c_E). Material Number: 11097536. The potential for intermittent well-to-well bias on the A1c_E assay on the Atellica CH and Atellica CI analyzer which could cause falsely depressed or falsely elevated HbA1c patient results. Material Number: 11097536. UDI-DI: 00630414220505. All Lot Numbers. Distribution: Worldwide distribution - US Nationwide and the countries of Argentina, Australia, Austria, Bahamas, Bangladesh, Bolivia, Brazil, Bulgaria, Burkina¿Faso, Canada, Chile, China, Colombia, Croatia, Cura¿ao,¿St¿Eus, Czech¿Republic, Democratic Republic Congo, Denmark, Ecuador, Egypt, El Salvador, Estonia, Finland, France, Georgia, Germany, Greece, Hong Kong, India, Indonesia, Israel, Italy, Japan, Jordan, Kenya, Kuwait, Latvia, Lebanon, Lithuania, Macedonia, Malaysia, Mexico, Netherlands, New Zealand, Norway, Oman, Pakistan, Paraguay, Poland, Portugal, Qatar, Republic of Korea, Romania, Saudi¿Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, Spain, Switzerland, Thailand, Turkey, Turkmenistan, U.A.E., Uganda, United¿Kingdom, Uruguay, Vatican City, Vietnam. Affected quantity: 24,077 units
- Hazard
- The potential for intermittent well-to-well bias on the A1c_E assay on the Atellica CH and Atellica CI analyzer which could cause falsely depressed or falsely elevated HbA1c patient results.
More from Siemens
See all- Siemens Atellica CH HDL reagent recalled for possible false test results
ModerateFDANov 6, 2026
- Siemens Syva EMIT 2000 Quinidine Assay recalled for inaccurate test results
SeriousFDAAug 26, 2026